Literature DB >> 16927141

Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents.

Feng-Chiao Tsai1, Song-Chou Hsieh, Ding-Shinn Chen, Jin-Chuan Sheu, Chien-Hung Chen, Ding-Shinn Chen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16927141     DOI： 10.1007/s10620-006-9074-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.487


× No keyword cloud information.
  40 in total

1.  Chronic hepatitis B: update of recommendations.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

Review 2.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update.

Authors:  Yun-Fan Liaw; Nancy Leung; Richard Guan; George K K Lau; Ismail Merican; Geoff McCaughan; Edward Gane; Jia-Horng Kao; Masao Omata
Journal:  Liver Int       Date:  2005-06       Impact factor: 5.828

3.  A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial.

Authors:  J H Hoofnagle; G L Davis; S C Pappas; R G Hanson; M Peters; M I Avigan; J G Waggoner; E A Jones; L B Seeff
Journal:  Ann Intern Med       Date:  1986-01       Impact factor: 25.391

4.  Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4-year experience.

Authors:  C J Liu; M Y Lai; P H Lee; N K Chou; S H Chu; P J Chen; J H Kao; Y M Jen; D S Chen
Journal:  J Gastroenterol Hepatol       Date:  2001-09       Impact factor: 4.029

5.  Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis.

Authors:  Y F Liaw; C M Chu; I J Su; M J Huang; D Y Lin; C S Chang-Chien
Journal:  Gastroenterology       Date:  1983-02       Impact factor: 22.682

6.  Randomized, double-blind, placebo-controlled trial of oromucosal low-dose interferon following prednisone withdrawal for chronic hepatitis B infection in Filipino patients.

Authors:  Thelma E Tupasi; Vilma M Co; Ma Socorro M Clarin; Evelyn T Alesna; Ella Mae S Divinagracia; Nellie V Mangubat
Journal:  Int J Infect Dis       Date:  2002-03       Impact factor: 3.623

Review 7.  Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue.

Authors:  Sandro Vento; Francesca Cainelli; Maria Serena Longhi
Journal:  Lancet Oncol       Date:  2002-06       Impact factor: 41.316

8.  Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial.

Authors:  R P Perrillo; F G Regenstein; M G Peters; K DeSchryver-Kecskemeti; C J Bodicky; C R Campbell; M C Kuhns
Journal:  Ann Intern Med       Date:  1988-07-15       Impact factor: 25.391

9.  Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours.

Authors:  C G Alexopoulos; M Vaslamatzis; G Hatzidimitriou
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

10.  Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy.

Authors:  W Yeo; B Zee; S Zhong; P K S Chan; W-L Wong; W M Ho; K C Lam; P J Johnson
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640
View more
  8 in total

1.  Outcome in a patient with systemic lupus erythematosus and concurrent chronic hepatitis B infection.

Authors:  Lyubomir Marinchev; Krasimir Antonov; Veneta Peytcheva; Zlatimir Kolarov
Journal:  BMJ Case Rep       Date:  2010-03-26

2.  Chronic hepatitis B in children with or without malignancies: a 13-year follow-up.

Authors:  Merve Usta; Nafiye Urgancı; Zeynep Yıldız Yıldırmak; Sema Dogan Vural
Journal:  World J Gastroenterol       Date:  2015-02-21       Impact factor: 5.742

3.  Reactivation of hepatitis B: pathogenesis and clinical implications.

Authors:  Anthony Post; Shweta Nagendra
Journal:  Curr Infect Dis Rep       Date:  2009-03       Impact factor: 3.725

4.  Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression.

Authors:  Tara N Palmore; Neeral L Shah; Rohit Loomba; Brian B Borg; Uri Lopatin; Jordan J Feld; Farooq Khokhar; Glen Lutchman; David E Kleiner; Neal S Young; Richard Childs; A John Barrett; T Jake Liang; Jay H Hoofnagle; Theo Heller
Journal:  Clin Gastroenterol Hepatol       Date:  2009-07-01       Impact factor: 11.382

5.  Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders.

Authors:  Umut Kalyoncu; Ozlem Yonem; Meral Calguneri; Osman Ersoy; Omer Karadag; Ali Akdogan; Sule A Bilgen; Sedat Kiraz; Ihsan Ertenli; Yusuf Bayraktar
Journal:  Rheumatol Int       Date:  2008-11-27       Impact factor: 2.631

6.  Seroprevalence of hepatitis B and C among oncology patients in Turkey.

Authors:  Sukran Kose; Ali Olmezoglu; Ayhan Gozaydin; Gulfem Ece
Journal:  J Health Popul Nutr       Date:  2011-12       Impact factor: 2.000

7.  Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C.

Authors:  Ioanna Aggeletopoulou; Christos Konstantakis; Spilios Manolakopoulos; Christos Triantos
Journal:  World J Gastroenterol       Date:  2017-06-28       Impact factor: 5.742

8.  Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections.

Authors:  Ying-Ming Chiu; Mei-Shu Lai; K Arnold Chan
Journal:  PLoS One       Date:  2018-04-25       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.